SAN DIEGO -- Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with ...

Among trial finishers, omalizumab and oral immunotherapy offered similar protection against food allergies, and some people ...

A service disruption on campus brought down many University services and applications for much of Thursday, though the issue ...

OIT, the most common approach to treating food allergy in the United States, involves eating gradually increasing doses of a food allergen to reduce the allergic response to it. Of the study ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very ...

Thirty-six percent of patients treated with omalizumab were able to tolerate 2000mg of peanut protein and 2 other food allergens without experiencing an allergic reaction compared with 19% of OIT ...

OIT, the most common approach to treating food allergy in the United States, involves eating gradually increasing doses of a food allergen to reduce the allergic response to it.

88% of the omalizumab group and 51% of the OIT group completed treatment. There were no serious adverse events with omalizumab. SAN DIEGO — Patients with three different food allergies who used ...

Stage 2 of the NIH-sponsored phase 3 OUtMATCH trial—the first head-to-head study of Xolair versus OIT—met its primary endpoint, Roche's Genentech said in a Sunday press release. The trial ...